sponsored
PatientsVille.com Logo

PatientsVille

Bevacizumab Medical Research Studies

Up-to-date List of Bevacizumab Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Bevacizumab Medical Research Studies

Rank Status Study
1 Unknown  Intralesional Bevacizumab Injection on Primary Pterygium
Conditions: Pterygium;   Inflammation
Interventions: Drug: Intralesional injection of Bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
Outcome Measure: percentage of corneal pterygium area
2 Recruiting Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
Condition: Retinopathy of Prematurity
Intervention: Procedure: Injection of Bevacizumab intravitreal (Avastin)
Outcome Measure: Regression of Retinopathy of prematurity
3 Recruiting Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: TPI 287;   Drug: Bevacizumab
Outcome Measures: Phase 1: Safety of TPI 287 + Bevacizumab in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis;   Phase 1: MTD of TPI 287 + Bevacizumab in adults with GBM that progressed following radiation & TMZ;   Phase 2: Efficacy of phase 1 MTD of TPI 287 + Bevacizumab versus Bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by median PFS;   Phase 1: Efficacy of TPI 287 + Bevacizumab in adults with GBM that progressed following radiation and TMZ as measured by median progression free survival (PFS), overall response rate, & progression free survival rate at 4 & 6 months (PFS4 & PFS6);   Phase 2: Safety of TPI 287 + Bevacizumab versus Bevacizumab alone in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis;   Phase 2: Efficacy of phase 1 MTD of TPI 287 + Bevacizumab versus Bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by overall survival and overall response rate
4 Recruiting Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Condition: Glioblastoma Multiforme
Interventions: Drug: TPI 287;   Drug: Bevacizumab
Outcome Measures: Safety of TPI 287 + Bevacizumab in adults with GBM that progressed following radiation & TMZ & prior Bevacizumab as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis;   MTD of TPI 287 + Bevacizumab in adults with GBM that progressed following radiation & TMZ & prior Bevacizumab;   Efficacy of TPI 287 + Bevacizumab in adults with GBM that progressed following radiation & TMZ & prior Bevacizumab as measured by median progression free survival (PFS), overall response rate, & PFS rate at 4 & 6 months (PFS4 & PFS6)
5 Recruiting Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Condition: Brain Cancer
Interventions: Drug: Vorinostat;   Drug: Bevacizumab
Outcome Measures: Progression Free Survival (PFS);   Maximum tolerated dose (MTD)
6 Recruiting Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Condition: Malignant Glioma (WHO Grade III or IV)
Interventions: Drug: CTO and Bevacizumab;   Drug: CTO alone
Outcome Measures: Phase 1: Determine the Maximum Tolerated Dose (MTD) of CTO when combined with standard dosing of Bevacizumab;   Phase 2: Percentage of subjects who remain alive and progression-free at 6 months;   Phase 1: Number of subjects who experience a dose-limiting toxicity (DLT) during cycle 1;   Phase 2: Percentage of subjects who experience a dose-limiting toxicity (DLT) during any cycle of protocol treatment;   Phase 2: Median Overall Survival (OS);   Phase 2: 6 and 12 month Overall Survival (OS);   Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) or partial response (PR);   Phase 2: Median PFS;   Phase 2: 12 month PFS
7 Unknown  Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Condition: Brain Tumors
Intervention: Drug: Neuradiab in combination with Bevacizumab (Avastin)
Outcome Measures: The safety of Neuradiab® when followed by Avastin therapy will be assessed based on Investigator reported symptomatic toxicity findings on physical exam, and Adverse Events.;   Overall survival (OS). Data will be reported based on a dataset of 60 patients.;   Time to progression (TTP). Data will be reported based on a dataset of 60 patients.
8 Recruiting Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Conditions: Brain Cancer;   Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab;   Drug: Low Dose Bevacizumab;   Drug: Lomustine
Outcome Measure: Number of Patients with PFS
9 Recruiting Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
Outcome Measures: Maximum Tolerated Dose (MTD) of Bevacizumab and Temsirolimus and/or Cetuximab or Valproic Acid;   Tumor Response
10 Recruiting A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions: Biological: Bevacizumab;   Drug: CPT-11 (Irinotecan);   Drug: 5-FU Bolus;   Drug: 5-FU Infusion;   Drug: l-LV (dl-LV);   Biological: Bevacizumab;   Drug: Capecitabine
Outcome Measures: Overall survival;   Progression-free survival (PFS);   Time to treatment failure (TTF);   Overall Response Rate (ORR);   Disease Control Rate (DCR);   Relative Dose Intensity;   Incidence of Adverse Events (Adverse Reactions);   Correlation between UGT1A1 genotype and safety
11 Recruiting NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Biological: Bevacizumab;   Device: NovoTTF-l00A;   Other: Quality of Life Assessment
Outcome Measures: Progression Free Survival (PFS);   Objective response rate based on RANO Criteria;   Number of patients that experience toxicities with this combination of therapies;   Median overall survival;   To assess time-to-progression;   Neurocognitive function (NCF);   Quality of Life (QOL)
12 Recruiting Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: Bevacizumab;   Drug: BKM120
Outcome Measures: To establish the optimal dose of BKM120 that can be administered in combination with a standard dose of Bevacizumab. (Phase I);   To evaluate the efficacy of the BKM120/Bevacizumab combination in patients with relapsed/refractory GBM.;   To evaluate the toxicity of the BKM120/Bevacizumab combination.;   To evaluate the pharmacokinetics of BKM120 when administered concurrently with Bevacizumab
13 Not yet recruiting Study to Compare and Evaluate the Pharmacokinetic (PK) and Safety Profile of Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) as First-line Treatment in Patients With Metastatic ColoRectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer.
Interventions: Drug: Experimental: Bevacizumab biosimilar (BEVZ92).;   Drug: Active Comparator: Avastin® (Bevacizumab, reference product)
Outcome Measures: To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI;   Safety, immunogenicity and efficacy profile
14 Recruiting Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Conditions: Diabetes;   Diabetic Macular Oedema;   Diabetic Macular Edema;   Diabetic Retinopathy
Interventions: Drug: Avastin (Bevacizumab);   Drug: Ozurdex (dexamethasone)
Outcome Measures: Proportion of eyes that have central macular thickness <300 microns 6 months after switching;   Mean change in central macular thickness (CMT) as measured by OCT.
15 Recruiting Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Condition: Lung Cancer
Interventions: Biological: Bevacizumab, erlotinib;   Drug: Bevacizumab, pemetrexed, cisplatin
Outcome Measures: Progression-free survival at 6 months in stratum wtEGFR cohort 1;   Progression-free survival;   Overall survival;   Best response (RECIST 1.1);   Adverse events (CTCAE v4.0);   Molecular markers in tumor tissue and blood
16 Recruiting Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
Condition: Advanced Non-squamous Non-Small Cell Lung Cancer
Interventions: Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg;   Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg
Outcome Measures: Does a higher dose of Bevacizumab have any effect on changes in blood pressure;   Response rate;   Change in tumor size;   Progression free survival
17 Recruiting Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Biological: anti-endoglin monoclonal antibody TRC105;   Biological: Bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
Outcome Measures: MTD of TRC105 combined with Bevacizumab based on the incidence of dose-limiting toxicity (DLT) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 (Phase I);   Progression-free survival (PFS) (Phase II);   Overall survival (Phase I and II);   PFS (Phase II);   Incidence of adverse events as assessed by NCI CTCAE v. 4.0 (Phase II);   QOL as assessed by the EORTC QLQ-C15-PAL and QLQ-BN20 Patient Questionnaires and the WIWI questionnaire (Phase II);   Objective response (Phase I);   Time until any treatment-related toxicity (Phase I);   Time until treatment-related grade 3+ toxicity (Phase I);   Time to progression (Phase I);   Time to treatment failure (Phase I)
18 Not yet recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-Bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
Outcome Measures: Quality Control Standards for Radiopharmamceuticals and Number of Successfully Acquired 89Zr-Bevacizumab-PET/CT scans;   Number of related adverse events after the intravenous administration of 89Zr-Bevacizumab.;   Biodistribution of 89Zr-Bevacizumab and individual organ and effective dose of 89Zr-Bevacizumab;   Amount of 89Zr-Bevacizumab uptake in IBC tumor and measures of tumor angiogenesis in research biopsy specimens.;   Changes in tumor uptake of 89Zr-Bevacizumab and FDG during and after preoperative chemotherapy and response in primary IBC tumor MRI.;   To correlate the changes in tumor uptake on 89Zr-Bevacizumab-PET/CT with standard imaging response using MRI and FDG-PET/CT
19 Recruiting Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Condition: Advanced Cancer
Interventions: Drug: Dasatinib;   Drug: Bevacizumab;   Drug: Paclitaxel
Outcome Measure: Maximum Tolerated Dose (MTD) of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone
20 Recruiting Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
Outcome Measures: To evaluate tumor responses to combination of irinotecan, temozolomide and Bevacizumab in patients with resistant NB.;   To determine the toxicity of the combination of irinotecan, temozolomide and Bevacizumab in patients with resistant NB.;   To evaluate changes in angiogenic markers after treatment with the combination of irinotecan, temozolomide and Bevacizumab.;   To measure time to progression in patients with resistant NB treated with the combination of irinotecan, temozolomide and Bevacizumab.

These studies may lead to new treatments and are adding insight into Bevacizumab etiology and treatment.

A major focus of Bevacizumab research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Bevacizumab